May 14, 2022 — Yesterday, FDA approved tirzepatide for type 2 diabetes, calling it “an important advance.” The brand name will be Mounjaro. This is the same drug for which its maker, Eli Lilly and Company, announced remarkable results in a phase 3 obesity study barely two weeks ago. It is the first of its kind – a dual […]
April 28, 2022 — Make no mistake. The competition to deliver better therapies for obesity is heating up in an impressive way. This morning, Eli Lilly released topline results for their first phase three trial of tirzepatide in obesity. One word sums up the reaction from top clinical scientists in obesity: “Wow!” Jeff Emmick is the vice president of […]
February 9, 2022 — There’s a race heating up. It is a race to open the way for better obesity care and deliver better options. In this race, semaglutide (Wegovy™) has a head start. But a pack of other options are on the way. Yesterday in JAMA, results in a study of tirzepatide for treating type 2 diabetes tell […]
January 12, 2022 — It’s been a long haul. But suddenly, we’re seeing a lot of optimism about anti-obesity medicines. Skeptics are yielding to stubborn facts about the impact of obesity on health. They are also yielding to good clinical data about the benefits of sound obesity care. So, too, are they seeing that newer generations of anti-obesity medicines […]
October 20, 2021 — Day by day, the prospects for treating obesity are getting better. Late on Monday, detailed results from the longest study yet of tirzepatide came out in Lancet. This was a study using this new drug in people with type 2 diabetes, but the average BMI of these patients was 33. None of them had a […]
June 26, 2021 — Semaglutide is getting a lot of attention right now because of its impressive effectiveness for treating obesity. But it may not have the spotlight all to itself for long. A new study in the New England Journal of Medicine tells us that tirzepatide will be giving semaglutide some serious competition. This study was for treating […]
June 8, 2021 — The mantra for the Wegovy brand of semaglutide just approved by FDA for obesity is clear enough – game changer. Great. Obesity is not a game, but health plans treat it like a 19th century game of hot potato: “Jack’s alive, and likely to live If he dies in your hand, you’ve a forfeit to […]
May 22, 2021 — Anyone following the news on progress with anti-obesity meds might have noticed a rising number of news reports about various “tides” for obesity. Liraglutide is already out there. So is setmelanotide. Semaglutide injection is under review at FDA and approval is possible as early as the middle of this year. Tirzepatide is advancing in clinical […]
February 22, 2021 — When NEJM recently published impressive results for a new obesity treatment, it caused quite a stir. Now it looks like semaglutide might have some serious competition coming right behind it. Late last week, Lilly announced results for two phase 3 studies of tirzepatide. These were both studies for type-2 diabetes. Effects on body weight were […]
December 18, 2020 — What’s been on your mind this year? One way to answer that question is to look at what grabbed your attention here on ConscienHealth. It’s been a year of keen interest in what we’re writing about. Almost half a million of you have taken time to read what we’ve written so far this year – […]
